HERV-K antigens, antibodies, and methods
Methods and compositions for cancer diagnostics and therapy are provided. More particular, methods and compositions for detecting, preventing, and treating HERV-K + cancers are provided. One example of a method may involve a method for preventing or inhibiting cancer cell proliferation by administering to a subject a cancer cell proliferation blocking or reducing amount of a HERV-K env protein binding antibody.
1. A monoclonal antibody specifically binding the HERV-K antigen comprising the following:
a CDR-H1 comprising SEQ ID NO:56;
a CDR-H2 comprising SEQ ID NO:58;
a CDR-H3 comprising SEQ ID NO:60;
a CDR-L1 comprising SEQ ID NO:62;
a CDR-L2 comprising SEQ ID NO:64; and
a CDR-L3 comprising SEQ ID NO:66.
2. The antibody of claim 1 , further defined as comprising a heavy chain comprising SEQ ID NO:52 and a light chain comprising SEQ ID NO:54.
3. An ScFv comprising SEQ ID NO:50.
4. A monoclonal antibody specifically binding the HERV-K antigen comprising the following:
a CDR-H1 comprising SEQ ID NO:74;
a CDR-H2 comprising SEQ ID NO:76;
a CDR-H3 comprising SEQ ID NO:78;
a CDR-L1 comprising SEQ ID NO:80;
a CDR-L2 comprising SEQ ID NO:82; and
a CDR-L3 comprising SEQ ID NO:84.
5. The antibody of claim 4 , further defined as comprising a heavy chain comprising SEQ ID NO:70 and a light chain comprising SEQ ID NO:72.
6. A humanized ScFv comprising SEQ ID NO:68.